Robert A Hauser

22PUBLICATIONS

54CO-AUTHORS

Liquid biopsiesMolecular targetsDental therapeutics, pharmacology and toxicologyOrthodontics and dentofacial orthopaedicsMortality

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (22)

Sort by Publication Date:

|May 07, 2026

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

|Feb 20, 2026

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

M H Werner, A McGarry, C Meyer

|Feb 04, 2026

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real-World Early Experience Program.

Laxman Bahroo, Aaron Ellenbogen, Robert A Hauser

|Dec 13, 2025

LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.

Anthony E Lang, Robert A Hauser, Lorraine V Kalia

|Mar 26, 2025

Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA.

Aaron Ellenbogen, Robert A Hauser, Atul T Patel

|Mar 24, 2025

Burden of tremor in Parkinson's disease: A survey study.

Robert A Hauser, Tara Crowder Skarpaas, Andréa Merriam

Pageof 4

Frequent Collaborators

Anette Schrag

M H Werner

A McGarry

K Kieburtz

K Shannon

A Park

P Mazzeo

M Lew

S Parashos

Jonathan M Meyer

Frequent Collaborators

Anette Schrag

M H Werner

A McGarry

K Kieburtz